Karyopharm Therapeutics (NASDAQ:KPTI) Posts Quarterly Earnings Results

Karyopharm Therapeutics (NASDAQ:KPTI) issued its quarterly earnings data on Tuesday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01, Zacks reports. The firm had revenue of $38.78 million for the quarter, compared to analysts’ expectations of $37.86 million. During the same period in the previous year, the business posted ($0.30) EPS. Karyopharm Therapeutics updated its FY 2024 guidance to EPS.

Karyopharm Therapeutics Price Performance

Shares of KPTI opened at $0.94 on Friday. The firm has a 50 day simple moving average of $0.81 and a 200-day simple moving average of $0.91. Karyopharm Therapeutics has a 1-year low of $0.62 and a 1-year high of $1.95. The stock has a market cap of $116.58 million, a price-to-earnings ratio of -0.75 and a beta of 0.16.

Analyst Ratings Changes

Several brokerages have issued reports on KPTI. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, November 1st. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Royal Bank of Canada restated an “outperform” rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Piper Sandler raised their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Robert W. Baird reduced their price objective on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $5.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).